Hospital Pharmacy Operations, Formulary Management, and Clinical Protocols
Administrative Structure and Learning Outcomes
Key Personnel:
- Jenna Maker
- Sara Mahmoud
Core Clinical Competencies:
- Application of common hospital processes to patient care, including order sets, protocols, clinical practice guidelines, antibiograms, and health system formularies.
- Entry, evaluation, and verification of electronic medication orders.
- Documentation of pharmacist clinical interventions within patient electronic health records.
- Execution of medication reconciliation processes and comprehensive discharge medication counseling.
- Utilization of proper aseptic technique for the compounding of sterile intravenous medications.
- Delivery of oral and written medication counseling to hospitalized patients preparing for discharge.
Platform Requirements:
- Access to EHR-Go learning software.
- Access to Penguin software.
- Schedule details hosted on Canvas.
Grading Assessment Scheme:
- In-class assignments and quizzes: of final grade.
- Aseptic Technique Objective Structured Clinical Examination (OSCE): of final grade.
- Discharge Counseling OSCE: of final grade.
Hospital Pharmacy Scope of Practice and Inpatient Clinical Services
Inpatient Clinical Services Managed by Pharmacists:
- Medication order entry and verification.
- Pharmacokinetic dosing and monitoring: Vancomycin PK/AUC determinations and aminoglycoside monitoring.
- Anticoagulant management protocols: Heparin continuous IV infusions, warfarin dosing, argatroban monitoring, and direct oral anticoagulant (DOAC) protocols.
- Total Parenteral Nutrition (TPN) formulation and management protocols.
- Antimicrobial Stewardship Programs (ASP).
- Protocol Autonomy: Clinical pharmacists operate relatively independently under hospital-approved protocols to execute these clinical services.
Secondary Clinical and Administrative Responsibilities:
- Transitions of Care (TOC): Conducting medication reconciliations and discharge counseling.
- Educational Delivery: Conducting formal and informal drug education for pharmacy staff, medical staff, and nursing personnel.
- Regulatory Adherence: Ensuring operational compliance with standards established by The Joint Commission, State Boards of Pharmacy, the Drug Enforcement Administration (DEA), and internal hospital policies and procedures.
- Committee Representation: Active involvement in interprofessional committees, including Pharmacy and Therapeutics (P&T) and Infection Control committees.
- Emergency Response: Functioning as primary responders to hospital emergency calls requiring a licensed pharmacist, such as Code Blue resuscitation events.
- Clinical Specialization: Advanced practice involvement in specialized clinical areas including Oncology, Infectious Diseases (ID), and Intensive Care Units (ICU).
Formulary Structure and Governance
ASHP Definition of Formulary:
- A formulary is a continually updated list of available medications and related information, representing the clinical judgment, resulting from a review of the clinical evidence, of clinicians in the diagnosis, prophylaxis, or treatment of disease and promotion of health.
Operational Definition:
- A formulary represents the explicit list of pharmaceutical agents routinely stocked and maintained within a healthcare system.
Formulary Governance:
- The Pharmacy & Therapeutics (P&T) committee is the organizational body responsible for developing, managing, evaluating, and updating the health system formulary.
Prescribing and Dispensing Restrictions:
- Prescribing Criteria Restrictions: Requirement for patients to meet established clinical criteria prior to drug dispensing. Example: Aztreonam is restricted solely to patients with a documented, severe anaphylactic allergy to beta-lactam antibiotics.
- Medical Service Restrictions: Requirement for specific specialist service authorization prior to medication approval. Example: Amphotericin B requires Infectious Diseases (ID) consult approval.
- Patient Care Area Restrictions: Dispensing limited to specific physical patient units. Example: Neuromuscular blocking agents are restricted to the Operating Room (OR) and Intensive Care Units (ICU).
Non-Formulary (NF) Medication Protocols:
- Operational Framework: Formal exception processes exist to request and acquire non-formulary agents when specific, unique clinical needs cannot be met using standard formulary drugs.
- Clinical Justifications: Documented severe drug allergy to all formulary options, or documented therapeutic failure on formulary alternatives.
- Operational Verification Workflow:
- Confirm whether the non-formulary agent is physically in stock or requires external ordering (identifying potential dispensing delays).
- Assess whether the patient can utilize their personal home medication supply under hospital custody guidelines.
Master Health System Formulary Sample Reference
iron sucrose (Venofer):
- Pharmacologic Class: Hematology-Oncology, Nutrition-Iron Homeostasis, Minerals.
- Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
isoflurane (Forane):
- Pharmacologic Class: Anesthesia, Anesthetics (General).
- Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
isoniazid PO (Generic):
- Pharmacologic Class: Antimicrobials, Tuberculosis (TB).
- Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Formulary.
isoproterenol (Isuprel):
- Pharmacologic Class: Cardiovascular, Antiarrhythmics (Parenteral).
- Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
isosorbide dinitrate (Isordil):
- Pharmacologic Class: Cardiovascular, Vasodilators/Nitrates.
- Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
isosorbide mononitrate (Generic):
- Pharmacologic Class: Cardiovascular, Vasodilators/Nitrates.
- Status: Inpatient = Formulary; Clinic = Other; Custody = Non-formulary; Outpatient = Formulary.
isosulfan blue 1% (Generic):
- Pharmacologic Class: Diagnostic.
- Status: Inpatient = Restricted; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
- Specific Restrictions: Restricted to Operating Room use only.
isotretinoin (Accutane):
- Pharmacologic Class: Dermatologic, Acne (Systemic).
- Status: Inpatient = Restricted; Clinic = Restricted; Custody = Restricted; Outpatient = Restricted.
- Specific Restrictions: and capsules only; restricted to Dermatology services.
isradipine (Generic):
- Pharmacologic Class: Cardiovascular, Calcium Channel Blockers (Dihydropyridine).
- Status: Inpatient = Restricted; Clinic = Restricted; Custody = Non-formulary; Outpatient = Restricted.
- Specific Restrictions: Pediatric Specialty Clinic use limited to pediatric patients; Inpatient use limited to Pediatric and Pediatric Intensive Care Unit (PICU) floors.
itraconazole (Generic):
- Pharmacologic Class: Antimicrobials, Dental-Oral Care Antifungals, Candidiasis (Oropharyngeal).
- Status: Inpatient = Restricted; Clinic = Non-formulary; Custody = Non-formulary; Outpatient = Formulary.
- Specific Restrictions: Refer to Enterprise policy #0009 Inpatient Restricted.
ivermectin (Stromectol):
- Pharmacologic Class: Antimicrobials, Antiparasitics.
- Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
ketamine (Generic, Ketalar):
- Pharmacologic Class: Anesthesia, Anesthetics (General), Sedation.
- Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
ketoconazole (Generic):
- Pharmacologic Class: Antimicrobials, Antifungals.
- Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
ketoconazole topical (Nizoral Topical):
- Pharmacologic Class: Antimicrobials, Dermatologic, Antifungals (Topical), Seborrhea/Dandruff.
- Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Formulary.
Antimicrobial Stewardship Tier Categorization
Tier Definitions and Approval Framework:
- Tier 1 (Infectious Diseases Restriction): Full restriction to the Infectious Disease (ID) service. Requires direct pre-approval from the ID Consult Service or the Antimicrobial Stewardship Program (ASP) Service.
- Tier 2 (Pharmacy Approval): Pharmacy approval may be granted for clinical scenarios meeting specific pre-approved criteria. Unapproved scenarios require formal authorization from ID or the ASP Service within .
- Tier 3 (Protected): Unrestricted agents that undergo routine retrospective review by the ASP Service.
- Tier 4 (Unrestricted): Unrestricted agents that are not regularly reviewed by the ASP Service.
Tier Classification Table:
- Tier 1 Agents (ID Restriction):
- Caspofungin (Non-formulary)
- Ceftaroline (Non-formulary)
- Ceftazidime/avibactam (Non-formulary)
- Ceftolozane/tazobactam (Non-formulary)
- Colistimethate intravenous (Restricted)
- Dalbavancin (Non-formulary)
- Delafloxacin (Non-formulary)
- Eravacycline (Restricted)
- Flucytosine (Restricted)
- Foscarnet (Non-formulary)
- Isavuconazole (Non-formulary)
- Meropenem/vaborbactam (Non-formulary)
- Quinupristin/dalfopristin (Restricted)
- Imipenem/cilastatin/relabactam (Restricted)
- Streptomycin (Non-formulary)
- Omadecycline (Non-formulary)
- Oritavancin (Non-formulary)
- Plazomicin (Non-formulary)
- Polymyxin B intravenous (Non-formulary)
- Tigecycline (Non-formulary)
- Tier 2 Agents (Pharmacy Approval):
- Amphotericin B lipid formulation (Abelcet or Ambisome) (Restricted)
- Aztreonam (Restricted)
- Daptomycin (Restricted)
- Ertapenem (Restricted)
- Fidaxomicin (Restricted)
- Fosfomycin (Restricted)
- Ganciclovir (Restricted)
- Imipenem/cilastatin (Restricted)
- Itraconazole (Restricted)
- Linezolid (Restricted)
- Meropenem (Restricted)
- Micafungin (Restricted)
Tier 2 Antimicrobial Usage Criteria
Amphotericin B Lipid Formulation (Abelcet or Ambisome):
- Pre-approved Indications (must meet at least one):
- Candidal endophthalmitis, endocarditis, or central nervous system infection.
- Cryptococcal meningitis.
- Zygomycoses.
- Neutropenic Fever accompanied by a documented fungal infection or failure of empiric antibacterial therapy.
- Severe coccidioidomycosis infections.
- Disseminated histoplasmosis infections.
- Alternative agent for invasive aspergillosis.
- Alternative agent for candidemia.
- Unacceptable Usage Criteria:
- Management of Candida infections susceptible to alternative agents.
Aztreonam:
- Pre-approved Indications:
- Severe, documentable allergy (e.g., anaphylaxis) to all other beta-lactam classes, including penicillins, cephalosporins, and carbapenems.
Daptomycin:
- Pre-approved Indications (must meet at least one):
- Vancomycin allergy combined with bacteremia caused by MRSA/Coagulase Negative Staphylococcus spp. (CONS) or endocarditis caused by MRSA/CONS.
- Infections caused by Vancomycin-Resistant S. aureus (VRSA).
- MRSA bacteremia or endocarditis in patients failing vancomycin therapy, where failure is defined as:
- Clinical decompensation after of therapy.
- Persistent bacteremia despite of vancomycin therapy with documented serum troughs of .
- Vancomycin MIC > (requires ID notification).
- Continuation of daptomycin therapy initiated at an outside transfer facility.
- Bone and joint infections supported by documented MRSA culture (excluding screening swabs).
- Unacceptable Usage Criteria (must not meet any):
- Treatment of pneumonia, due to drug inactivation by pulmonary surfactant.
- Initial empiric therapy for Gram-positive infections (excluding patients transferred from an outside hospital on established daptomycin therapy).
- Vancomycin-Resistant Enterococcus (VRE) colonization isolated from urine, respiratory tract, wounds, or surgical drains.
Ertapenem:
- Pre-approved Indications (must meet all criteria):
- Documented infection caused by an extended-spectrum beta-lactamase (ESBL) producing organism.
- ESBL isolate confirmed susceptible to ertapenem via laboratory testing.
Therapeutic Interchange Regulations and Execution
Definition and Scope:
- Therapeutic interchange involves dispensing a medication that is therapeutically equivalent to the original medication ordered by a prescriber.
- Authorizes pharmacists to automatically substitute a formulary therapeutic alternative in place of a non-formulary drug or a non-preferred formulary agent without prior prescriber contact.
- Exceptions to standard interchange protocols include drug backorders or authorization for a patient to use their personal home medication supply.
Clinical Verification Responsibilities:
- Pharmacists must exercise independent clinical judgment and refrain from executing a therapeutic interchange if specific patient contraindications or clinically significant drug-drug interactions (DDIs) exist.
- The evaluating pharmacist is required to consult drug reference materials to determine maximum dosing limits and renal dose adjustments prior to processing an interchange.
- Critical product categories requiring heightened monitoring during evaluation include:
- Biosimilars.
- Immediate-Release (IR) versus Extended-Release (ER) or Controlled-Release (CR) formulations.
- Fixed-dose combination products.
Angiotensin II Receptor Antagonist Therapeutic Interchange Guidelines
Interchange Formatting Rules:
- BOLD text denotes formulary status.
- PREFERRED indicates the first-line formulary selection. Non-preferred formulary options may be used if preferred options are unavailable or contraindicated due to allergy or intolerance.
- Non-formulary options are reserved for special circumstances such as manufacturer backorders.
Heart Failure Protocol (HFrEF Specific):
- Scope: Applies to patients with Heart Failure with reduced Ejection Fraction (HFrEF). Interchanges are strictly limited to Losartan, Candesartan, and Valsartan.
- Bi-directional Dose Equivalencies (Once Daily Only):
- Losartan (Cozaar) (PREFERRED) Valsartan (Diovan) (FORMULARY) Candesartan (Atacand) (NON-PREFERRED).
- Losartan (Cozaar) (PREFERRED) Valsartan (Diovan) (FORMULARY) Candesartan (Atacand) (NON-PREFERRED).
- Losartan (Cozaar) (PREFERRED) Valsartan (Diovan) (FORMULARY) Candesartan (Atacand) (NON-PREFERRED).
- Valsartan (Diovan) (FORMULARY) Candesartan (Atacand) (NON-PREFERRED).
Non-Heart Failure Indications Protocol:
- Scope: Applies solely to non-heart failure indications. Irbesartan and Olmesartan are not indicated for heart failure and cannot be used in HFrEF patients.
- Bi-directional Dose Equivalencies (Once Daily Only):
- Losartan (PREFERRED) Valsartan (FORMULARY) Candesartan (NON-PREFERRED) Olmesartan (Benicar) (NON-PREFERRED) Irbesartan (Avapro) (NON-PREFERRED).
- Losartan (PREFERRED) Valsartan (FORMULARY) Candesartan (NON-PREFERRED) Olmesartan (NON-PREFERRED) Irbesartan (NON-PREFERRED).
- Losartan (PREFERRED) Valsartan (FORMULARY) Candesartan (NON-PREFERRED) Olmesartan (NON-PREFERRED) Irbesartan (NON-PREFERRED).
- Valsartan (FORMULARY) Candesartan (NON-PREFERRED).
Clinical Antibiograms and Infectious Disease Workflow
Antibiogram Definition and Purpose:
- An antibiogram is a periodic report summarizing aggregate antimicrobial susceptibilities of local bacterial isolates analyzed by a institutional microbiology laboratory.
- Functions:
- Evaluation of local bacterial susceptibility rates.
- Selection guidance for empiric antimicrobial therapy prior to culture confirmation.
- Long-term monitoring of resistance pattern trends within an institution.
Organizational Structure of Antibiograms:
- Antibiograms are facility-specific and typically updated on an annual basis.
- Data is stratified by clinical care setting:
- Inpatient medical/surgical floors.
- Outpatient departments / Emergency Room (ER).
- Intensive Care Units (ICU).
- Certain reports isolate urinary tract specimens from non-urinary tract specimens.
Clinical Infection Management Workflow:
- Step 1: Patient develops clinical signs and symptoms of infection.
- Step 2: Microbiological cultures are collected and submitted to the laboratory.
- Step 3: Patient is initiated on EMPIRIC antibiotic therapy. Antibiograms are utilized directly at this step to guide empiric drug selection based on local susceptibility patterns.
- Step 4: Cultures successfully isolate the causative microorganism and susceptibility profiles are determined.
- Step 5: Patient is transitioned to DEFINITIVE antibiotic therapy tailored specifically to the isolated pathogen.
Institutional Antibiogram Reference Data
Dataset Overview:
- Reporting Period: 01/01/2021 to 12/31/2021.
- Laboratory Supervision: Stuart Cohen, M.D., Director, Clinical Microbiology Laboratory (UC Davis Health Antimicrobial Stewardship Program).
- Target Population/Setting: Pediatric Inpatient ICU - Gram Positive Organisms.
Antimicrobial Susceptibility Percentages ():
Staphylococcus aureus, all ():
Erythromycin:
Clindamycin:
Levofloxacin:
Tetracycline:
Minocycline:
Gentamicin:
Daptomycin:
Linezolid:
Rifampin:
Trimethoprim/Sulfamethoxazole:
Vancomycin:
Staphylococcus aureus, MSSA ():
Oxacillin:
Cefazolin:
Erythromycin:
Clindamycin:
Levofloxacin:
Trimethoprim/Sulfamethoxazole:
Vancomycin:
Staphylococcus aureus, MRSA ():
Oxacillin:
Cefazolin:
Erythromycin:
Clindamycin:
Levofloxacin:
Tetracycline:
Minocycline:
Gentamicin:
Daptomycin:
Linezolid:
Rifampin:
Trimethoprim/Sulfamethoxazole:
Vancomycin:
Coagulase Negative Staphylococci ():
Oxacillin susceptibility documented per Clinical and Laboratory Standards Institute (CLSI) breakpoints ( for Staph spp; for CONS).
Enterococcus species, all ():
Penicillin G:
Ampicillin:
Gentamicin (High Level):
Streptomycin (High Level):
Daptomycin:
Linezolid:
Vancomycin:
Enterococcus faecalis ():
Penicillin G:
Ampicillin:
Linezolid:
Vancomycin:
Enterococcus faecium ():
Penicillin G:
Ampicillin:
Linezolid:
Vancomycin: